September 16, 2024 10:57 AM EDT
News Briefing

Nu­va­len­t's $350M of­fer­ing; FDA lifts par­tial hold on Zen­tal­is drug

ENDPOINTS

Plus, news about As­cendis Phar­ma, Ko­r­ro Bio, No­vo Nordisk and Medexus:

Nu­va­lent of­fers $350M in shares: The on­col­o­gy biotech is look­ing to

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

SiteOne Ther­a­peu­tics, a pain biotech that's part­nered with Ver­tex, nabs $100M

Au­ri­on’s eye cell ther­a­py im­proves vi­sion in small study, plots Phase 3 tri­al

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

A service from the Financial Times